Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments
March 5 (Reuters) - Tenaya Therapeutics TNYA.O said on Thursday it has signed a research deal with Alnylam Pharmaceuticals ALNY.O worth up to $1.13 billion to develop treatments for heart diseases.
Shares of Tenaya were up more than 11% in premarket trading.
Here are some details:
Tenaya said it will work on heart disease–focused treatments that target up to 15 genetic causes during a two‑year research period.
Alnylam will handle all further drug development and take full responsibility for commercialization of any medicines that come out of the collaboration, Tenaya said.
The company said it could receive up to $10 million in upfront payments and additional research funding from Alnylam. It may also be eligible for up to $1.13 billion in milestone payments if the drugs are successfully developed and approved.
Alnylam's major growth driver is Amvuttra, which treats a heart condition known as transthyretin amyloid cardiomyopathy (ATTR-CM). Amvuttra recorded sales of $2.31 billion in 2025.
